Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed,
and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government
operating status and resumption of normal operations can be found at opm.gov.
Effect of Intravitreal Bevacizumab on Corneal Endothelium
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01726790
Verified November 2012 by Kasem Yospaiboon, Khon Kaen University. Recruitment status was: Recruiting
To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection
Condition or disease
Corneal Endothelial Cell Loss
Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 80 Years (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patient in retinalvascular clinic with diagnosis of retinal vein occlusion with macular edema, diabetic macular edema, wet aged related macular degeneration and submacular hemorrhage)treated with intravitreal Bevacizumab
aged between 20 and 80 years old
can come to regular follow up at 6 month
signed written consent forms
not have corneal scar, or glaucoma
history of treatment with laser or anti-VEGF therapy in 3 month prior to recruit
high risk in cerebrovascular and cardiovascular diseases
Pregnancy and breastfeeding
can undergo confocal microspopy
History of intraocular surgery or ocular trauma during study